SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...
Phase 1b/2 dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer. This is an ...
BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today ...
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases ...
Enliven Therapeutics Inc. has synthesized HER2 (erbB2) inhibitors, including Exon 20 insertion (Ex20Ins) mutant inhibitors, reported to be useful for the treatment of cancer.
Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling. Estelamari Rodriguez, M.D., MPH: Hello, and ...
There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access ...
"For the majority of people with advanced EGFR-mutated NSCLC, we have highly effective targeted treatment options. However, for a minority with EGFR exon 20-mutated disease, these treatments don’t ...
Activating mutations on the EGFR protein, including exon 20 insertion mutations, have a role in NSCLC, but the associated structural changes resulting from the V769insASV and D770insNPG EGFR exon 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results